Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. Further, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRIB
CUSIPN/A
Phone353-1276-9800
Debt
Debt-to-Equity Ratio1.45
Current Ratio5.03
Quick Ratio3.49
Price-To-Earnings
Trailing P/E Ratio31.13
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$99.14 million
Price / Sales1.05
Cash Flow$0.3116 per share
Price / Cash15.98
Book Value$2.71 per share
Price / Book1.84
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-40,270,000.00
Net Margins-41.88%
Return on Equity3.45%
Return on Assets1.29%
Miscellaneous
Employees582
Outstanding Shares20,930,000
Market Cap$104.23
Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions
What is Trinity Biotech's stock symbol?
Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."
How were Trinity Biotech's earnings last quarter?
Trinity Biotech plc (NASDAQ:TRIB) announced its quarterly earnings results on Thursday, July, 19th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.03. The business earned $25 million during the quarter. Trinity Biotech had a positive return on equity of 3.45% and a negative net margin of 41.88%. View Trinity Biotech's Earnings History.
When is Trinity Biotech's next earnings date?
What is the consensus analysts' recommendation for Trinity Biotech?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trinity Biotech in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Trinity Biotech's key competitors?
Some companies that are related to Trinity Biotech include Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Trinity Biotech's key executives?
Trinity Biotech's management team includes the folowing people:
- Mr. Ronan O'Caoimh, Co-Founder, Chairman and Chief Exec. Officer (Age 62)
- Mr. Kevin Tansley, Chief Financial Officer, Sec. and Director (Age 47)
- Dr. James Walsh Ph.D., Bus. Devel. Director and Exec. Director (Age 60)
Has Trinity Biotech been receiving favorable news coverage?
News articles about TRIB stock have trended somewhat positive this week, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trinity Biotech earned a coverage optimism score of 0.12 on Accern's scale. They also gave news articles about the company an impact score of 44.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Trinity Biotech?
Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trinity Biotech's stock price today?
One share of TRIB stock can currently be purchased for approximately $4.98.
How big of a company is Trinity Biotech?
Trinity Biotech has a market capitalization of $104.23 million and generates $99.14 million in revenue each year. Trinity Biotech employs 582 workers across the globe.
How can I contact Trinity Biotech?
Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]
MarketBeat Community Rating for Trinity Biotech (NASDAQ TRIB)
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
